ERBB2 and breast cancer: Taking into account the BC subtype, [18F]FDG PET/CT has shown good performance in predicting early pathological complete response (pCR) in TNBC [[92], [93], [94], [95], [96], [97], [98], [99], [100], [101]] and HER2+ BC [95,[102], [103], [104], [105], [106], [107]], pCR being associated with a better survival [108].